Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament comprising inhibitors of long pentraxin ptx3

A long pentraxin and inhibitor technology, applied in the field of medicines containing long pentraxin PTX3 inhibitors, can solve the problems of infection and increased susceptibility to reproductive infertility and the like

Inactive Publication Date: 2007-01-10
DEFIANTE FARM
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, inhibiting the expression of proteins that play fundamental roles in important biological functions at the genetic level may cause adverse reactions such as increased susceptibility to infection and reproductive infertility

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] PTX3-deficient mice are used as a murine model of collagen-induced arthritis (CIA) (Campbell et al., Eur. J. Immunol, 2000; 30:1568-75). The purpose of the experiment is to evaluate the susceptibility of PTX3- / - mice to the induction of arthritis phenotype.

[0025] In the proximal region of the tail, multiple intradermal injections were used to treat 129 sv with 100μg of chicken type II collagen (SIGMA) in a total volume of 100μl, supplemented with 250μg of heat-inactivated Mycobacterium tuberculosis Freund's complete adjuvant. x C57 BL / 6PTX3- / - mice.

[0026] The same treatment was performed 21 days later.

[0027] At the end of the dosing period, an arbitrary scoring system that calculates the presence of inflamed joints and their size is used to evaluate the incidence and severity of arthritis. The results obtained are listed in Table 1.

[0028] The greater incidence of PTX3+ / + mice reported in Table 1 provides evidence that PTX3- / - mice are less susceptible to collage...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The use of inhibitors of long pentraxin PTX3 for the preparation of a medicament for the prevention and treatment of autoimmune diseases and of degenerative diseases of bone and cartilage is described.

Description

[0001] The invention described herein relates to the use of long pentraxin PTX3 inhibitors in the preparation of drugs for the treatment of autoimmune diseases and bone and cartilage degenerative diseases. Background of the invention [0002] PTX3 is a glycoprotein that can spontaneously organize itself in a homodecameric structure bound by a disulfide bridge. It is expressed in different types of cells (Bottazzi et al., J. Biol. Chem. , 1997;272:32817-32823), especially expressed in monocytes and endothelial cells after contact with the inflammatory cytokines interleukin 1β (IL-1β) and tumor necrosis factor α (TNF-α). [0003] PTX3 consists of two domains: the N-terminus, which is not related to any known molecule, and the C-terminus, which is similar to short pentraxins such as C-reactive protein (CRP). A high degree of similarity between human PTX3 (hPTX3) and animal PTX3 has been found. [0004] For a review of pentraxin, see H. Gewurz et al., Current Opinion ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K38/17A61P37/00A61P19/00A01K67/027C07K14/47C07K16/18C12N15/85
CPCA01K2217/075C12N15/8509C07K16/18C07K14/4737A01K2227/105A01K2267/03A61K2039/505A61K38/1709A01K67/0275C07K2316/96A61P1/04A61P1/16A61P3/10A61P5/14A61P7/06A61P13/12A61P15/00A61P17/00A61P19/00A61P19/02A61P19/10A61P21/00A61P21/04A61P25/00A61P27/02A61P29/00A61P35/00A61P37/00A61P43/00A61K39/395
Inventor B·伯塔兹P·卡尔米纳蒂C·戈兰达A·曼托瓦尼
Owner DEFIANTE FARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com